Safety and Efficacy of COVID-19 Hyperimmune Globulin (HIG) Solution in the Treatment of Active COVID-19 infection- Findings from a Prospective, Randomized, Controlled, Multi-Centric Trial

Devang Parikh, Alok Chaturvedi, Naman Shah, Piyush Patel, Ronak Patel, Suma Ray

Devang Parikh, Alok Chaturvedi, Naman Shah, Piyush Patel, Ronak Patel, Suma Ray

Keywords: convalescent plasma, COVID-19, hyperimmune globulin, Neutralizing antibodies, plasma-derived product, SARS-CoV-2

Abstract

Background: COVID-19 hyper-immune globulin (HIG) solution is a human plasma-derived, highly-purified, concentrated, virus-inactivated preparation of neutralizing antibodies (NAbs) against COVID-19.
Material & Methods: This was a randomized, two-arm, controlled, multi-center trial to evaluate the efficacy and safety of COVID-19 HIG in patients who were hospitalized with moderate-severe COVID-19 infection.
Results: A total of 60 patients were randomized (30 in each arm). Overall, COVID-19 HIG was well-tolerated without any serious treatment-emergent adverse event or tolerability issue. The mean change in ordinal scale by day 8 was 1.7±1.61 in the test arm vs. 2.0±1.68 in the control arm (mITT; p=0.367). Early and high NAbs were observed in the test arm compared to the control arm. More patients had negative RT-PCR by day 3 for the test arm vs. the control arm (mITT: 46.67% in test vs. 37.93% in control). The median time to be RT-PCR negative was 5.5 days for the test arm vs. 8.0 days for the control arm for PP population.
Patients receiving COVID-19 HIG showed early improvement (reduction) in the biomarkers (CRP, IL-6, and D-dimer).
Conclusion: COVID-19 HIG was found to be safe and well-tolerated. Early and high NAbs were achieved in COVID-19 HIG recipients qualifying the product as a suitable treatment option, particularly in an immunocompromised state. It should be given early in infection to mitigate progression to severe disease. It should also be evaluated for post-exposure prophylaxis as well as for prevention (where a vaccine is not suitable or effective). HIG should be evaluated in the pediatric population as well.
Clinical Trial registration number: CTRI/2020/09/027903
Conflict of Interest: DP, AC, PP, SR are employees of Intas Pharmaceuticals Ltd. NS and RP are employees of Lambda Therapeutics Research Ltd. The authors declare no other potential conflicts of interest
Source/s of Support: This trial was sponsored and funded by Intas Pharmaceuticals Ltd., India

References

1. Keller MA, Stiehm ER. Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev. 2000;13(4):602-614.
2. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. Cited 2021 May 16. Available from: https://covid19.who.int/.
3. Salzberger B, Buder F, Lampl B. Ehrenstein B, Hitzenbichler F, Holzmann T, et al. Epidemiology of SARS-CoV-2. Infection. 2021;49:233–239 DOI: 10.1007/s15010-020-01531-3.